HC Wainwright Comments on Oculis' Q3 Earnings (NASDAQ:OCS)

Key Points

• HC Wainwright raised its Q3 2026 EPS estimate for Oculis to a loss of $0.47 per share from a previous loss estimate of $0.48, while maintaining a “Buy” rating.
• Analyst sentiment is broadly favorable, with nine Buy ratings and one Sell rating, producing a “Moderate Buy” consensus and an average price target of $39.44.
• Oculis shares opened at $7.87, near their 52-week low of $7.11 and well below the $34.47 high; the company reported a $0.20 quarterly loss on $0.38 million in revenue in its latest results.

Oculis Holding AG (NASDAQ:OCS - Free Report) - Stock analysts at HC Wainwright lifted their Q3 2026 earnings per share (EPS) estimates for shares of Oculis in a research note issued to investors on Tuesday, October 20th. HC Wainwright analyst Y. Chen now anticipates that the company will earn ($0.47) per share for the quarter, up from their prior estimate of ($0.48). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Oculis' current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Oculis' Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($1.72) EPS, Q1 2027 earnings at ($0.47) EPS, Q2 2027 earnings at ($0.47) EPS, Q3 2027 earnings at ($0.47) EPS, Q4 2027 earnings at ($0.47) EPS and FY2027 earnings at ($1.90) EPS.

Oculis (NASDAQ:OCS - Get Free Report) last posted its earnings results on Tuesday, June 30th. The company reported ($0.20) earnings per share for the quarter. The business had revenue of $0.38 million for the quarter. Oculis had a negative return on equity of 42.61% and a negative net margin of 6,777.18%.

Other research analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. lowered their target price on shares of Oculis from $23.00 to $20.00 and set an "overweight" rating for the company in a report on Friday, August 14th. Wall Street Zen raised shares of Oculis from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 8th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Oculis in a research note on Thursday, October 15th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Oculis has an average rating of "Moderate Buy" and an average price target of $39.44.

Oculis Stock Performance

Shares of Oculis stock opened at $7.87 on Thursday. The company has a quick ratio of 8.35, a current ratio of 8.35 and a debt-to-equity ratio of 0.01. Oculis has a 52 week low of $7.11 and a 52 week high of $34.47. The firm's 50 day moving average is $10.44 and its two-hundred day moving average is $16.01. The firm has a market capitalization of $456.33 million, a P/E ratio of -4.52 and a beta of 0.62.

Institutional Investors Weigh In On Oculis

Several large investors have recently modified their holdings of OCS. Koshinski Asset Management Inc. acquired a new position in shares of Oculis in the 1st quarter valued at $238,000. Himension Capital Singapore PTE. LTD. purchased a new stake in Oculis in the 1st quarter valued at $503,000. Y Intercept Hong Kong Ltd acquired a new stake in Oculis during the 1st quarter worth $776,000. Squarepoint Ops LLC boosted its stake in Oculis by 326.4% during the 2nd quarter. Squarepoint Ops LLC now owns 61,605 shares of the company's stock worth $854,000 after purchasing an additional 47,158 shares during the period. Finally, Bank of America Corp DE grew its position in Oculis by 9.1% during the 1st quarter. Bank of America Corp DE now owns 69,764 shares of the company's stock worth $1,855,000 after purchasing an additional 5,813 shares during the last quarter. 22.30% of the stock is owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis NASDAQ: OCS is a biopharmaceutical company focused on developing and commercializing innovative treatments for eye diseases. The company aims to address significant unmet needs in ophthalmology through therapies designed for topical, noninvasive administration and other targeted delivery approaches.

Oculis' pipeline has included OCS-01, a topical dexamethasone formulation being developed for retinal diseases such as diabetic macular edema, and licaminlimab (OCS-02), an ophthalmic anti-TNF biologic being investigated for conditions including dry eye disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.